Luka de Vos

675 total citations
22 papers, 470 citations indexed

About

Luka de Vos is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Luka de Vos has authored 22 papers receiving a total of 470 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 10 papers in Oncology and 10 papers in Immunology. Recurrent topics in Luka de Vos's work include Epigenetics and DNA Methylation (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Genomics and Diagnostics (6 papers). Luka de Vos is often cited by papers focused on Epigenetics and DNA Methylation (11 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Cancer Genomics and Diagnostics (6 papers). Luka de Vos collaborates with scholars based in Germany, Australia and United States. Luka de Vos's co-authors include Dimo Dietrich, Friedrich Bootz, Glen Kristiansen, Jennifer Landsberg, Heidrun Gevensleben, Alina Franzen, Joerg Wenzel, Romina Zarbl, Andreas Schröck and Jörn Dietrich and has published in prestigious journals such as Clinical Chemistry, Oncotarget and Epigenetics.

In The Last Decade

Luka de Vos

22 papers receiving 467 citations

Peers

Luka de Vos
Ambra V. Gualeni Italy
Hiroyuki Goda Japan
Ngar‐Woon Kam China
Martha Zavridou Greece
Catherine Riley United Kingdom
Krishnan K. Mahadevan United States
Tieneke B.M. Schaaij‐Visser Netherlands
Roselle J. Eisma United States
Yu Ishizuya Japan
Bo Gong Japan
Ambra V. Gualeni Italy
Luka de Vos
Citations per year, relative to Luka de Vos Luka de Vos (= 1×) peers Ambra V. Gualeni

Countries citing papers authored by Luka de Vos

Since Specialization
Citations

This map shows the geographic impact of Luka de Vos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luka de Vos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luka de Vos more than expected).

Fields of papers citing papers by Luka de Vos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luka de Vos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luka de Vos. The network helps show where Luka de Vos may publish in the future.

Co-authorship network of co-authors of Luka de Vos

This figure shows the co-authorship network connecting the top 25 collaborators of Luka de Vos. A scholar is included among the top collaborators of Luka de Vos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luka de Vos. Luka de Vos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vos, Luka de, Romina Zarbl, Judith Sirokay, et al.. (2024). Circulating Cell-Free SHOX2 DNA Methylation Is a Predictive, Prognostic, and Monitoring Biomarker in Adjuvant and Palliative Anti-PD-1-Treated Melanoma. Clinical Chemistry. 70(3). 516–527. 3 indexed citations
2.
Niebel, Dennis, et al.. (2023). Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions. American Journal of Clinical Dermatology. 24(4). 521–540. 32 indexed citations
3.
Hoffmann, Friederike, Alina Franzen, Luka de Vos, et al.. (2023). CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma. Clinical Epigenetics. 15(1). 112–112. 15 indexed citations
4.
Ralser, Damian J., Luka de Vos, Romina Zarbl, et al.. (2023). ICOS DNA methylation regulates melanoma cell-intrinsic ICOS expression, is associated with melanoma differentiation, prognosis, and predicts response to immune checkpoint blockade. Biomarker Research. 11(1). 56–56. 4 indexed citations
5.
Hoffmann, Friederike, Anne Fröhlich, Judith Sirokay, et al.. (2023). DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma. Melanoma Research. 33(2). 116–125. 3 indexed citations
6.
Dietrich, Dimo, Luka de Vos, Timo Vogt, et al.. (2023). Circulating Cell-Free SEPT9 DNA Methylation in Blood Is a Biomarker for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma Patients. Clinical Chemistry. 69(9). 1050–1061. 9 indexed citations
7.
Braegelmann, Christine, et al.. (2022). Current Concepts on Pathogenic Mechanisms and Histopathology in Cutaneous Lupus Erythematosus. Frontiers in Medicine. 9. 915828–915828. 18 indexed citations
8.
Vos, Luka de, et al.. (2022). Characterization of B cells in lupus erythematosus skin biopsies in the context of different immune cell infiltration patterns. Frontiers in Medicine. 9. 1037408–1037408. 5 indexed citations
9.
10.
Vos, Luka de, Romina Zarbl, Niklas Klümper, et al.. (2022). CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1-Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma. Journal of Immunotherapy. 45(7). 324–334. 12 indexed citations
11.
12.
Dietrich, Jörn, Timo Vogt, Roland H. Stauber, et al.. (2020). The DNA Methylation Landscape of PD-1 ( PDCD1 ) and Adjacent LncRNA AC131097.3 in Head and Neck Squamous Cell Carcinoma. Epigenomics. 13(2). 113–127. 10 indexed citations
13.
Vos, Luka de, Maria Jung, Emma Bawden, et al.. (2020). Treatment Response Monitoring in Patients with Advanced Malignancies Using Cell-Free SHOX2 and SEPT9 DNA Methylation in Blood. Journal of Molecular Diagnostics. 22(7). 920–933. 22 indexed citations
14.
Vos, Luka de, Emma Bawden, Jörn Dietrich, et al.. (2020). The landscape of CD28, CD80, CD86, CTLA4, and ICOS DNA methylation in head and neck squamous cell carcinomas. Epigenetics. 15(11). 1195–1212. 33 indexed citations
15.
Vos, Luka de, Jörn Dietrich, Sebastian Strieth, et al.. (2020). PD-1 , CTLA4 , PD-L1 and PD-L2 DNA Methylation in Papillary Thyroid Carcinoma. Immunotherapy. 12(12). 903–920. 8 indexed citations
16.
Holderried, Tobias A.W., Luka de Vos, Emma Bawden, et al.. (2019). Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma. Clinical Epigenetics. 11(1). 161–161. 54 indexed citations
17.
Vos, Luka de, Heidrun Gevensleben, Andreas Schröck, et al.. (2017). Comparison of quantification algorithms for circulating cell-free DNA methylation biomarkers in blood plasma from cancer patients. Clinical Epigenetics. 9(1). 125–125. 38 indexed citations
18.
Goltz, Diane, Heidrun Gevensleben, Luka de Vos, et al.. (2017). PDCD1 (PD-1) promoter methylation predicts outcome in head and neck squamous cell carcinoma patients. Oncotarget. 8(25). 41011–41020. 40 indexed citations
19.
Schröck, Andreas, Luka de Vos, Heidrun Gevensleben, et al.. (2017). Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. Clinical Chemistry. 63(7). 1288–1296. 96 indexed citations
20.
Sailer, Verena, Emily Eva Holmes, Heidrun Gevensleben, et al.. (2016). PITX2andPANCRDNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma. Oncotarget. 7(46). 75827–75838. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ambra V. Gualeni Breakdown of academic impact, for papers by Hiroyuki Goda Breakdown of academic impact, for papers by Ngar‐Woon Kam Breakdown of academic impact, for papers by Martha Zavridou Breakdown of academic impact, for papers by Catherine Riley Breakdown of academic impact, for papers by Krishnan K. Mahadevan Breakdown of academic impact, for papers by Tieneke B.M. Schaaij‐Visser Breakdown of academic impact, for papers by Roselle J. Eisma Breakdown of academic impact, for papers by Yu Ishizuya Breakdown of academic impact, for papers by Bo Gong
Rankless by CCL
2026